Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves Β· freshest Wall Street data, updated daily View live feed β†’
Analyst Tracker/Joon Lee
UBS

Joon Lee

Wall Street Analyst
β˜…β˜…β˜…β˜†β˜†
#2211
on 13Foresight Β· ranked by our own returns
49%
Success Rate
+2.3%
Average Return
29 of 59 calls profitable Β· -3.4% vs benchmark
S&P 500 (SPY)
πŸ“ˆ Across the calls we could measure, roughly 49% of Joon Lee's ratings turned a profit when each position was held for 1 year β€” averaging +2.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

78 Buy 7 Hold 0 Sell
Joon's Stock Coverage 38 ratings Β· 2026-11-17
Company Date Position Consensus β“˜ Price Target β“˜ 1-Yr Return vs S&P 500 β“˜
BBIO
BridgeBio Pharma
Oct 30, 2026 BUY Strong Buy
+26.1% avg upside
36 analysts
$92.00
22.78% Upside
+2.5% Β·
PTCT
PTC Therapeutics
Oct 30, 2026 BUY Buy
+35.4% avg upside
29 analysts
$90.00
50.12% Upside
+0.7% Β·
ALNY
Alnylam Pharma
Oct 30, 2026 BUY Strong Buy
+76.3% avg upside
53 analysts
$329.00
99.30% Upside
-5.1% Β·
VKTX
Viking Therapeutics
Oct 29, 2026 BUY Strong Buy
+172.0% avg upside
31 analysts
$94.00
244.54% Upside
+0.1% Β·
WVE
Wave Life Sciences
Oct 28, 2026 BUY Strong Buy
+443.5% avg upside
30 analysts
$11.00
206.31% Upside
-22.0% Β·
REGN
Regeneron
Oct 16, 2026 BUY Strong Buy
-12.2% avg upside
60 analysts
$978.00
5.30% Upside
+21.1% Β·
ASND
Ascendis Pharma
Oct 16, 2026 BUY Strong Buy
+12.3% avg upside
29 analysts
$269.00
7.12% Upside
+20.4% Β·
IONS
Ionis Pharmaceuticals
Oct 16, 2026 BUY Strong Buy
+74.1% avg upside
44 analysts
$88.00
102.31% Upside
-37.7% Β·
BMRN
BioMarin Pharmaceutical
Oct 15, 2026 BUY Strong Buy
+63.6% avg upside
52 analysts
$88.00
50.48% Upside
+4.4% Β·
PRAX
Praxis Precision Medicines
Oct 15, 2026 BUY Strong Buy
+99.2% avg upside
25 analysts
$706.00
146.94% Upside
+6.1% Β·
SLDB
Solid Biosciences
Oct 15, 2026 BUY Strong Buy
+176.4% avg upside
26 analysts
$20.00
222.62% Upside
+8.5% Β·
CRSP
Crispr Therapeutics AG
Oct 15, 2026 HOLD Buy
+45.6% avg upside
41 analysts
$52.00
1.23% Upside
-22.1% Β·
QURE
uniQure
Oct 15, 2026 BUY Strong Buy
+121.1% avg upside
30 analysts
$48.00
93.32% Upside
-7.7% Β·
RARE
Ultragenyx Pharmaceutical
Oct 15, 2026 HOLD Strong Buy
+193.8% avg upside
36 analysts
$16.00
0.60% Downside
+10.1% Β·
ARWR
Arrowhead Pharmaceuticals
Oct 15, 2026 BUY Strong Buy
+26.6% avg upside
29 analysts
$109.00
81.99% Upside
-18.3% Β·
VYGR
Voyager Therapeutics
Mar 17, 2026 BUY Strong Buy
+730.1% avg upside
23 analysts
β€” -61.2% Β·
EDIT
Editas Medicine
Mar 17, 2026 HOLD Buy
+398.6% avg upside
33 analysts
β€” -25.6% Β·
VRTX
Vertex Pharmaceuticals
Mar 11, 2026 BUY Strong Buy
-20.5% avg upside
62 analysts
$525.00
5.97% Downside
+8.5% Β·
ANAB
AnaptysBio
Mar 09, 2026 HOLD Strong Buy
+48.7% avg upside
26 analysts
$50.00
3.66% Upside
+14.6% Β·
CORT
Corcept Therapeutics
Mar 02, 2026 BUY Buy
-17.9% avg upside
16 analysts
β€” +94.8% Β·
NTLA
Intellia Therapeutics
Mar 02, 2026 BUY Buy
+187.2% avg upside
39 analysts
β€” -36.7% Β·
ALKS
Alkermes
Feb 26, 2026 BUY Strong Buy
-3.4% avg upside
34 analysts
β€” +47.7% Β·
JAZZ
Jazz Pharmaceuticals
Feb 25, 2026 BUY Strong Buy
+16.2% avg upside
36 analysts
β€” +16.4% Β·
AXSM
Axsome Therapeutics
Feb 24, 2026 BUY Strong Buy
+63.9% avg upside
30 analysts
β€” -20.0% Β·
RAPP
Rapport Therapeutics, Inc.
Nov 10, 2025 BUY Strong Buy
+158.1% avg upside
15 analysts
β€” +4.2% Β·
LRMR
Larimar Therapeutics
Nov 06, 2025 BUY Strong Buy
+621.1% avg upside
22 analysts
β€” -31.1% Β·
TSHA
Taysha Gene Therapies
Nov 05, 2025 BUY Strong Buy
+241.9% avg upside
22 analysts
β€” +1.5% Β·
ARGX
Argenx Se
Aug 01, 2025 BUY Strong Buy
-8.2% avg upside
48 analysts
β€” +26.7% Β·
KROS
Keros Therapeutics
Dec 04, 2024 BUY Strong Buy
+116.6% avg upside
21 analysts
β€” -70.1% Β·
CRMD
Cormedix
Nov 14, 2023 BUY Strong Buy
+165.8% avg upside
13 analysts
$18.00
216.06% Upside
+251.4% Β·
ARVN
Arvinas Holding Company
Jan 17, 2023 BUY Buy
+257.9% avg upside
28 analysts
$65.00
727.02% Upside
+11.1% Β·
RLMD
Relmada Therapeutics
Dec 08, 2022 HOLD Buy
+273.3% avg upside
15 analysts
$4.00
11.77% Upside
+18.0% Β·
KRSA
Korsana Biosciences
May 05, 2022 BUY Strong Buy
+27.8% avg upside
7 analysts
$14.00
53.58% Downside
-60.1% Β·
ELOX
Eloxx Pharmaceuticals
Aug 08, 2019 BUY Strong Buy
+168.9% avg upside
13 analysts
$10.00
25.57% Downside
Β· Β·
ABEO
Abeona Therapeutics
Jun 19, 2019 BUY Strong Buy
+295.1% avg upside
18 analysts
$20.00
359.72% Upside
Β· Β·
SRPT
Sarepta Therapeutics
Aug 08, 2014 BUY Buy
+223.8% avg upside
50 analysts
β€” +53.8% Β·
ACAD
ACADIA Pharmaceuticals
Aug 07, 2014 BUY Strong Buy
+71.5% avg upside
43 analysts
$33.00
60.32% Upside
+86.9% Β·
TLPH
Talphera
Jul 28, 2014 BUY Buy
+357.6% avg upside
15 analysts
$14.00
1259.28% Upside
Β· Β·
πŸ”’ 33 more ratings β€” with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Joon Lee β€” Frequently Asked Questions
How accurate are Joon Lee's stock ratings?
Based on the calls 13Foresight could measure, about 49% of Joon's ratings were profitable over a one-year hold, with an average return of +2.3% per rating, or -3.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Joon ranked on 13Foresight?
Joon Lee is currently ranked #2211 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge β€” so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Joon cover?
Joon most recently has ratings on BBIO, PTCT, ALNY, VKTX, WVE, REGN, ASND, IONS, BMRN, PRAX, SLDB, CRSP and 26 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.